Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2423 in mild COPD following LPS instillation
NCT01153321Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD2423 with Placebo (2 arms). Primary endpoint: Absolute Monocyte Count in BAL Post-LPS Challenge at Day 11. Started Oct 2010; status: completed.
02
Drugs
azd2423
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01153321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01153321.